NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView today published a Q&A feature with Dr. George Magrath, Chief Executive Officer of Opus Genetics, Inc. (“Opus Genetics” or the “Company”) ...

Patients with diabetic macular edema treated with intravitreal aflibercept have a significantly higher risk of adverse renal events compared with those treated with ranibizumab.

Vantage Biosciences has dosed the first subject in the randomised Phase II trial of oral therapy VX-01 to treat ...

Dr. Michael Kapusta, MD, FRSCS, Ophthalmologist, talks about advanced (proliferative) diabetic retinopathy and pars plana ...

A study analyzed the geographic and institutional disparities in clinical trial distribution for candidates targeting the ...

Gene therapy is an area of intensive research and development in the retina space, with promising prospects and significant challenges. The benefits and pitfalls of gene therapy were discussed by two ...

Below a specific threshold, FCP exerts a protective effect, but above that threshold the protective effect becomes uncertain.

PUDUCHERRY: In a major breakthrough, researchers at Pondicherry University have identified molecular markers in tear fluid that could enable early, non-invasive detection of diabetic retinopathy ...

Patients with retinopathy of prematurity are more likely to lose vision if they are Hispanic or undergo treatment in the South or Midwest.